€180 Million Life Sciences Fund Closes

XGEN Venture, a leading VC firm specializing in life sciences investments, proudly announces the final closing of its XGEN Venture Life Sciences Fund. This fund has successfully raised about €180 million in total commitments, surpassing expectations and solidifying its position as a key player in the European life sciences investment landscape.

This fund focuses on early-stage investments across biotechnology, medical devices, and diagnostics. And XGEN Venture employs a strategic approach, leveraging its extensive network of scientific experts, seasoned entrepreneurs, and industry leaders to accelerate growth and innovation within its portfolio companies, bringing transformative solutions to market.

XGEN Venture has already started deploying capital in six startups, recently adding tincture B.V.– a company pioneering therapies for neglected and hard-to-treat cancers – to previously announced investments. And the firm plans about nine additional investments over the next two to three years to complete the fund’s portfolio.

KEY QUOTES:

“We are thrilled to complete this fundraising journey with strong support from both existing and new investors. The tremendous interest in the XGEN Venture Life Sciences Fund underscores the critical importance of innovation in addressing today’s pressing healthcare challenges. This fund enables us to identify and support the next generation of groundbreaking life sciences companies.”

Paolo Fundarò, Co-Founder and Managing Partner at XGEN Venture

“Life sciences innovation is advancing at an unprecedented pace, and our investors recognize the opportunity to achieve impactful societal benefits alongside strong financial returns.”

Federica Draghi, Co-Founder and Managing Partner at XGEN Venture; Dr. Draghi also oversees the fund’s environmental, social, and governance (ESG) strategy.

“Our goal over the next years is to consolidate ourselves as one of the leading players in the European venture capital market. The remarkable success of our first fund and the exceptional team built since inception provide a solid foundation for reaching such an ambitious target.”